SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function.

Danii L S SuijkMichaël J B van BaarErik J M van BommelZainab IqbalMerle M KrebberVolker VallonDaan TouwEwout J HoornMax NieuwdorpMark M H KramerJaap A JolesPetter BjornstadDaniël H van Raalte

Published in: Clinical journal of the American Society of Nephrology : CJASN (2022)

Renoprotective Effects of Dapagliflozin in Type 2 Diabetes (RED), NCT02682563; SGLT2 Inhibition: Uric Acid Excretion Study (UREX), NCT05210517.

Keyphrases

uric acid
metabolic syndrome
type diabetes
cardiovascular disease
insulin resistance
skeletal muscle
diabetic nephropathy